Abstract
To evaluate the accuracy of contrast-enhanced {sup 18}F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: {<=}1 ng/ml, 1 to {<=}2 ng/ml, 2 to {<=}4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups {<=}1, 1 to {<=}2, 2 to {<=}4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA {<=}2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt {<=}6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve {<=}2 ng/ml per year. PET alone was positive
More>>
Schillaci, Orazio;
[1]
IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)];
Calabria, Ferdinando;
[2]
Tavolozza, Mario;
Caracciolo, Cristiana Ragano;
Orlacchio, Antonio;
Danieli, Roberta;
Simonetti, Giovanni;
[1]
Agro, Enrico Finazzi;
Miano, Roberto
[3]
- University ''Tor Vergata'', Department of Biopathology and Diagnostic Imaging, Interventional, Rome (Italy)
- IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)
- University Hospital ''Tor Vergata'', Department of Urology, Rome (Italy)
Citation Formats
Schillaci, Orazio, IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)], Calabria, Ferdinando, Tavolozza, Mario, Caracciolo, Cristiana Ragano, Orlacchio, Antonio, Danieli, Roberta, Simonetti, Giovanni, Agro, Enrico Finazzi, and Miano, Roberto.
Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
Germany: N. p.,
2012.
Web.
doi:10.1007/S00259-011-2030-7.
Schillaci, Orazio, IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)], Calabria, Ferdinando, Tavolozza, Mario, Caracciolo, Cristiana Ragano, Orlacchio, Antonio, Danieli, Roberta, Simonetti, Giovanni, Agro, Enrico Finazzi, & Miano, Roberto.
Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy.
Germany.
https://doi.org/10.1007/S00259-011-2030-7
Schillaci, Orazio, IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)], Calabria, Ferdinando, Tavolozza, Mario, Caracciolo, Cristiana Ragano, Orlacchio, Antonio, Danieli, Roberta, Simonetti, Giovanni, Agro, Enrico Finazzi, and Miano, Roberto.
2012.
"Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy."
Germany.
https://doi.org/10.1007/S00259-011-2030-7.
@misc{etde_21568770,
title = {Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy}
author = {Schillaci, Orazio, IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)], Calabria, Ferdinando, Tavolozza, Mario, Caracciolo, Cristiana Ragano, Orlacchio, Antonio, Danieli, Roberta, Simonetti, Giovanni, Agro, Enrico Finazzi, and Miano, Roberto}
abstractNote = {To evaluate the accuracy of contrast-enhanced {sup 18}F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: {<=}1 ng/ml, 1 to {<=}2 ng/ml, 2 to {<=}4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups {<=}1, 1 to {<=}2, 2 to {<=}4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA {<=}2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt {<=}6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve {<=}2 ng/ml per year. PET alone was positive in 31 of 49 patients (63.3%), and of these 31 patients, CT was negative in 14 but diagnosed bone lesions in 2 patients in whom PET alone was negative. CT with the administration of intravenous contrast medium did not provide any further information. Detection rate of {sup 18}F-choline imaging is closely related to PSA and PSA kinetics. In particular, {sup 18}F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt {<=}6 months and PSAve >2 ng/ml per year. CT is useful for detecting bone metastases that are not {sup 18}F-choline-avid. The use of intravenous contrast agent seems unnecessary. (orig.)}
doi = {10.1007/S00259-011-2030-7}
journal = []
issue = {4}
volume = {39}
place = {Germany}
year = {2012}
month = {Apr}
}
title = {Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced {sup 18}F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy}
author = {Schillaci, Orazio, IRCCS Neuromed, Department of Nuclear Medicine and Molecular Imaging, Pozzilli (Italy)], Calabria, Ferdinando, Tavolozza, Mario, Caracciolo, Cristiana Ragano, Orlacchio, Antonio, Danieli, Roberta, Simonetti, Giovanni, Agro, Enrico Finazzi, and Miano, Roberto}
abstractNote = {To evaluate the accuracy of contrast-enhanced {sup 18}F-choline PET/CT in restaging patients with prostate cancer after radical prostatectomy in relation to PSA, PSA velocity (PSAve) and PSA doubling time (PSAdt). PET/CT was performed in 49 patients (age range 58-87 years) with rising PSA (mean 4.13 ng/ml) who were divided in four groups according to PSA level: {<=}1 ng/ml, 1 to {<=}2 ng/ml, 2 to {<=}4 ng/ml, and >4 ng/ml. PSAve and PSAdt were measured. PET and CT scans were interpreted separately and then together. PET/CT diagnosed relapse in 33 of the 49 patients (67%). The detection rates were 20%, 55%, 80% and 87% in the PSA groups {<=}1, 1 to {<=}2, 2 to {<=}4 and >4 ng/ml, respectively. PET/CT was positive in 7 of 18 patients (38.9%) with a PSA {<=}2 ng/ml, and in 26 of 31 (83.9%) with a PSA >2 ng/ml. PET/CT was positive in 7 of 25 patients (84%) with PSAdt {<=}6 months, and in 12 of 24 patients (50%) with PSAdt >6 months, and was positive in 26 of 30 patients (86%) with a PSAve >2 ng/ml per year, and in 7 of 19 patients (36.8%) with PSAve {<=}2 ng/ml per year. PET alone was positive in 31 of 49 patients (63.3%), and of these 31 patients, CT was negative in 14 but diagnosed bone lesions in 2 patients in whom PET alone was negative. CT with the administration of intravenous contrast medium did not provide any further information. Detection rate of {sup 18}F-choline imaging is closely related to PSA and PSA kinetics. In particular, {sup 18}F-choline PET/CT is recommended in patients with PSA >2 ng/ml, PSAdt {<=}6 months and PSAve >2 ng/ml per year. CT is useful for detecting bone metastases that are not {sup 18}F-choline-avid. The use of intravenous contrast agent seems unnecessary. (orig.)}
doi = {10.1007/S00259-011-2030-7}
journal = []
issue = {4}
volume = {39}
place = {Germany}
year = {2012}
month = {Apr}
}